Evaluation of Phosphorylated Proteins Involved in the Epidermal Growth Factor Receptor (EGFR) Signaling Pathway to Predict the Response of Patients with Breast Cancer to Neoadjuvant Chemotherapy Regimens with Weekly Paclitaxel: Preliminary Analysis
Journal Title: Journal of Oncology and Cancer Research - Year 2017, Vol 1, Issue 1
Abstract
This preliminary analysis aimed at evaluating the capacity of epidermal growth factor receptor (EGFR) signaling pathway phosphorylated proteins as predictors of the pathologic response of breast cancer patients treated weekly with neoadjuvant paclitaxel. Pathologic response was graded based on the Miller-Payne system. The Luminex method was used to measure the phosphorylation state of 22 proteins involved in the EGFR signaling pathway in the tumor samples of 40 patients. Good pathologic response (≥ 90% tumor reduction) was observed in 10 patients. Comparing patients grouped as good and poor pathologic response to treatment, we found no statistically significant differences among the proteins analyzed. On the other hand, the percentage of tumor reduction after paclitaxel was inversely correlated to the expression of phosphorylated HER2 protein (Pearson correlation: r=-0.353; p=0.027). The current analysis demonstrated that the overexpression of phosphorylated HER2 (pY1023) in primary breast cancer tissue is predictive of lower response to weekly paclitaxel therapy. However, due to the high heterogeneity of breast cancer, the verification and predictive value of the overexpression of phosphorylated proteins requires further studies, with a larger number of patients, which may prompt more individualized treatment for cancer patients in the future.
Authors and Affiliations
Nilciza MCT Calux, Márcia DA SILVA-MAZON, Debora C Moreira, Tatiana CS Bonetti, Afonso CP Nazário, Ismael DCG Silva, Gil Facina
Keywords
Related Articles
- EP ID EP249325
- DOI 10.28967/jocr.2017.01.17006
- Views 104
- Downloads 0
Effect of Radiotherapy on Antioxidant Vitamin E in Patients with Carcinoma Uterine Cervix- a Pilot Study
Vitamin E, a fat-soluble antioxidant, stops the production of Reactive Oxygen Species (ROS) during the process of fat oxidation. It is used to prevent and repair normal tissue damage and to increase the susceptibility of...
Endothelin Signaling as Target for Anticancer Therapy: from Prostate Cancer to Multiple Myeloma
Neuropeptides including endothelin 1 (ET-1) are potent mitogens for both benign and malignant cells through G-protein receptor binding and signal transduction [1]. Aberrant expression of several components of the endothe...
Evaluation of Phosphorylated Proteins Involved in the Epidermal Growth Factor Receptor (EGFR) Signaling Pathway to Predict the Response of Patients with Breast Cancer to Neoadjuvant Chemotherapy Regimens with Weekly Paclitaxel: Preliminary Analysis
This preliminary analysis aimed at evaluating the capacity of epidermal growth factor receptor (EGFR) signaling pathway phosphorylated proteins as predictors of the pathologic response of breast cancer patients treated w...
The Epigenetic Theory of Carcinogenesis: p53 as the Guardian of The Epigenome
The principal advantage of the hypothesis that the multiple phenotypic abnormalities characteristic of malignant and pre-malignant cells result from epigenetic disorder is that it accounts for the wide spectrum of anomal...
Objectively Recorded Physical Activity And Perceived Distress At The Beginning Of Oncological Treatment
Purpose: To examine the association between physical activity (PA), objectively recorded as number of steps and hours of moderate- to- vigorous intensity PA, and self- reported distress (anxiety, depression, intrusion an...